Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Thursday that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) therapy.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal action date of 14 November 2026.
Summit's BLA submission is based on results from the global Phase III HARMONi study, which compared ivonescimab plus platinum-doublet chemotherapy with placebo plus platinum-doublet chemotherapy in previously TKI-treated patients. Over 14,000 patients in the United States are eligible for treatment in this setting, highlighting the significant unmet medical need addressed by ivonescimab.
The FDA plans to conduct a complete review following Good Review Management Principles, including mid-cycle and wrap-up meetings, and will propose labelling subject to the review outcome.
CStone Pharmaceuticals' sugemalimab granted new indication by UK MHRA
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons
Beyfortus study shows sustained reduction in infant RSV hospitalisations across two seasons
AstraZeneca reports positive Phase III results for BREZTRI in uncontrolled asthma
Akeso's AK139 Phase II clinical trials approved in China
Median Technologies secures FDA clearance for AI lung cancer screening software
Insilico Medicine names new vice president, Clinical Development – Oncology
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Guerbet's contrast agent Elucirem approved by European Commission in children from birth